158 related articles for article (PubMed ID: 35324925)
1. Epitope-based peptide vaccine design and elucidation of novel compounds against 3C like protein of SARS-CoV-2.
Sajid M; Marriam S; Mukhtar H; Sohail S; Sajid M; Sehgal SA
PLoS One; 2022; 17(3):e0264700. PubMed ID: 35324925
[TBL] [Abstract][Full Text] [Related]
2. Immunoinformatics and Molecular Docking Studies Predicted Potential Multiepitope-Based Peptide Vaccine and Novel Compounds against Novel SARS-CoV-2 through Virtual Screening.
Waqas M; Haider A; Rehman A; Qasim M; Umar A; Sufyan M; Akram HN; Mir A; Razzaq R; Rasool D; Tahir RA; Sehgal SA
Biomed Res Int; 2021; 2021():1596834. PubMed ID: 33728324
[TBL] [Abstract][Full Text] [Related]
3. Elucidation of novel compounds and epitope-based peptide vaccine design against C30 endopeptidase regions of SARS-CoV-2 using immunoinformatics approaches.
Marriam S; Afghan MS; Nadeem M; Sajid M; Ahsan M; Basit A; Wajid M; Sabri S; Sajid M; Zafar I; Rashid S; Sehgal SA; Alkhalifah DHM; Hozzein WN; Chen KT; Sharma R
Front Cell Infect Microbiol; 2023; 13():1134802. PubMed ID: 37293206
[TBL] [Abstract][Full Text] [Related]
4. Determine the Potential Epitope Based Peptide Vaccine Against Novel SARS-CoV-2 Targeting Structural Proteins Using Immunoinformatics Approaches.
Waqas M; Haider A; Sufyan M; Siraj S; Sehgal SA
Front Mol Biosci; 2020; 7():227. PubMed ID: 33195402
[TBL] [Abstract][Full Text] [Related]
5.
Devi A; Chaitanya NSN
J Biomol Struct Dyn; 2021 Nov; 39(18):6903-6917. PubMed ID: 32772892
[TBL] [Abstract][Full Text] [Related]
6. Applying high throughput and comprehensive immunoinformatics approaches to design a trivalent subunit vaccine for induction of immune response against emerging human coronaviruses SARS-CoV, MERS-CoV and SARS-CoV-2.
Rahmani A; Baee M; Saleki K; Moradi S; Nouri HR
J Biomol Struct Dyn; 2022 Aug; 40(13):6097-6113. PubMed ID: 33509045
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 and other human coronaviruses: Mapping of protease recognition sites, antigenic variation of spike protein and their grouping through molecular phylogenetics.
Chakraborty C; Sharma AR; Bhattacharya M; Saha RP; Ghosh S; Biswas S; Samanta S; Sharma G; Agoramoorthy G; Lee SS
Infect Genet Evol; 2021 Apr; 89():104729. PubMed ID: 33497837
[TBL] [Abstract][Full Text] [Related]
8. Mapping SARS-CoV-2 Antibody Epitopes in COVID-19 Patients with a Multi-Coronavirus Protein Microarray.
Camerini D; Randall AZ; Trappl-Kimmons K; Oberai A; Hung C; Edgar J; Shandling A; Huynh V; Teng AA; Hermanson G; Pablo JV; Stumpf MM; Lester SN; Harcourt J; Tamin A; Rasheed M; Thornburg NJ; Satheshkumar PS; Liang X; Kennedy RB; Yee A; Townsend M; Campo JJ
Microbiol Spectr; 2021 Oct; 9(2):e0141621. PubMed ID: 34704808
[TBL] [Abstract][Full Text] [Related]
9. Immunoinformatics-guided designing and in silico analysis of epitope-based polyvalent vaccines against multiple strains of human coronavirus (HCoV).
Sarkar B; Ullah MA; Araf Y; Islam NN; Zohora US
Expert Rev Vaccines; 2022 Dec; 21(12):1851-1871. PubMed ID: 33435759
[TBL] [Abstract][Full Text] [Related]
10. Immuno-Informatics Quest against COVID-19/SARS-COV-2: Determining Putative T-Cell Epitopes for Vaccine Prediction.
Akhtar N; Joshi A; Singh B; Kaushik V
Infect Disord Drug Targets; 2021; 21(4):541-552. PubMed ID: 32957905
[TBL] [Abstract][Full Text] [Related]
11. Whole proteome screening and identification of potential epitopes of SARS-CoV-2 for vaccine design-an immunoinformatic, molecular docking and molecular dynamics simulation accelerated robust strategy.
Ezaj MMA; Junaid M; Akter Y; Nahrin A; Siddika A; Afrose SS; Nayeem SMA; Haque MS; Moni MA; Hosen SMZ
J Biomol Struct Dyn; 2022 Sep; 40(14):6477-6502. PubMed ID: 33586620
[TBL] [Abstract][Full Text] [Related]
12. Integrative immunoinformatics paradigm for predicting potential B-cell and T-cell epitopes as viable candidates for subunit vaccine design against COVID-19 virulence.
Sarma VR; Olotu FA; Soliman MES
Biomed J; 2021 Aug; 44(4):447-460. PubMed ID: 34489196
[TBL] [Abstract][Full Text] [Related]
13. Design of a multi-epitope vaccine against SARS-CoV-2 using immunoinformatics approach.
Sanami S; Zandi M; Pourhossein B; Mobini GR; Safaei M; Abed A; Arvejeh PM; Chermahini FA; Alizadeh M
Int J Biol Macromol; 2020 Dec; 164():871-883. PubMed ID: 32682041
[TBL] [Abstract][Full Text] [Related]
14. Immunopeptidome profiling of human coronavirus OC43-infected cells identifies CD4 T cell epitopes specific to seasonal coronaviruses or cross-reactive with SARS-CoV-2.
Becerra-Artiles A; Nanaware PP; Muneeruddin K; Weaver GC; Shaffer SA; Calvo-Calle JM; Stern LJ
bioRxiv; 2022 Dec; ():. PubMed ID: 36482973
[TBL] [Abstract][Full Text] [Related]
15. Potential Immunogenic Activity of Computationally Designed mRNA- and Peptide-Based Prophylactic Vaccines against MERS, SARS-CoV, and SARS-CoV-2: A Reverse Vaccinology Approach.
Khan T; Khan A; Ansari JK; Najmi MH; Wei DQ; Muhammad K; Waheed Y
Molecules; 2022 Apr; 27(7):. PubMed ID: 35408772
[TBL] [Abstract][Full Text] [Related]
16. Bioinformatics analysis of epitope-based vaccine design against the novel SARS-CoV-2.
Chen HZ; Tang LL; Yu XL; Zhou J; Chang YF; Wu X
Infect Dis Poverty; 2020 Jul; 9(1):88. PubMed ID: 32741372
[TBL] [Abstract][Full Text] [Related]
17. Computationally validated SARS-CoV-2 CTL and HTL Multi-Patch vaccines, designed by reverse epitomics approach, show potential to cover large ethnically distributed human population worldwide.
Srivastava S; Verma S; Kamthania M; Agarwal D; Saxena AK; Kolbe M; Singh S; Kotnis A; Rathi B; Nayar SA; Shin HJ; Vashisht K; Pandey KC
J Biomol Struct Dyn; 2022 Mar; 40(5):2369-2388. PubMed ID: 33155524
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 coronavirus vaccine T cell epitope prediction analysis based on distributions of HLA class I loci (HLA-A, -B, -C) across global populations.
Cun Y; Li C; Shi L; Sun M; Dai S; Sun L; Shi L; Yao Y
Hum Vaccin Immunother; 2021 Apr; 17(4):1097-1108. PubMed ID: 33175614
[TBL] [Abstract][Full Text] [Related]
19. Immunopeptidome profiling of human coronavirus OC43-infected cells identifies CD4 T-cell epitopes specific to seasonal coronaviruses or cross-reactive with SARS-CoV-2.
Becerra-Artiles A; Nanaware PP; Muneeruddin K; Weaver GC; Shaffer SA; Calvo-Calle JM; Stern LJ
PLoS Pathog; 2023 Jul; 19(7):e1011032. PubMed ID: 37498934
[TBL] [Abstract][Full Text] [Related]
20. An overview on the seven pathogenic human coronaviruses.
Kesheh MM; Hosseini P; Soltani S; Zandi M
Rev Med Virol; 2022 Mar; 32(2):e2282. PubMed ID: 34339073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
